Could China’s Crackdown Go Beyond Apple? And Just How Big Can the Weight Loss Market Get? 9/7/23

7 Sep 2023 · 45 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Fast Money Podcast Summary: Episode - "Could China’s Crackdown Go Beyond Apple? And Just How Big Can the Weight Loss Market Get?" (9/7/23)

Episode Overview In this episode, the hosts, led by Melissa Lee, discuss the implications of Apple's stock drop due to a potential crackdown by China, alongside a significant forecast for the weight loss drug market. The roundtable features insights from top traders Tim Seymour, Karen Feinerman, Bono and Eisen, and Steve Grasso.

---

Key Discussions

  1. Apple’s Stock Drop
  2. Current Situation: Apple shares fell by 3% on the second consecutive day, with a total decline exceeding 6% over the past two sessions.
  3. Cause: The downturn began following reports of an expanded ban on iPhones from state-owned enterprises in China, impacting major suppliers like Qualcomm and Taiwan Semiconductor.
  4. Broader Impact: Concerns arise over whether this is indicative of a broader crackdown against other U.S. companies such as Nike and Starbucks.
  5. Expert Opinions:
  6. Tim Seymour: Stressed the importance of context and cautioned against overstating the significance of the ban, noting that consumers can still purchase iPhones outside of work constraints.
  7. Bono and Eisen: Suggested that the market might be pricing in overly pessimistic scenarios regarding Apple, indicating an irrational investor response.
  1. China’s Economic Context
  2. The discussion highlighted the struggling Chinese economy and how it could affect consumer behavior regarding foreign products, including iPhones.
  3. Market Dynamics: Potential consumers in China may opt for domestic alternatives like Huawei's Mate 60, especially given the political tension and changing consumer sentiment.
  1. Weight Loss Drug Market Potential
  2. Market Forecast: An analyst from J.P. Morgan predicts the market for weight loss drugs could reach a staggering $100 billion, with expectations of $50 billion by the decade's end.
  3. Key Players: Companies like Eli Lilly and Novo Nordisk are seen as significant beneficiaries of this growth.
  4. Skepticism and Concerns:
  5. Jared Holtz from Mizuho: Expressed caution regarding the long-term impacts of pricing and access for these drugs, as well as potential scrutiny from government entities.
  6. Market Dynamics: The success of these drugs in various applications (e.g., diabetes, obesity) raises questions about pricing strategies and potential backlash from payers.
  1. Broader Economic Indicators
  2. Host discussions included the implications of Walmart's decision to roll back employee wages, signaling changes in the labor market dynamics.
  3. The conversation extended to the potential impact of a United Auto Workers (UAW) strike and its implications for the automotive industry.
  1. Closing Insights
  2. The episode wrapped up with a look at IPO activity and the capital markets, mentioning upcoming IPOs like Arm and the overall outlook for the market.

---

Key Takeaways

  • Apple's Challenges: Ongoing geopolitical tensions and economic conditions in China pose significant risks for Apple and potentially other U.S. companies.
  • Weight Loss Market: While the projected growth of the weight loss drug market is promising, experts advise caution on the sustainability of such growth amidst regulatory pressures.
  • Economic Signals: Economic indicators, including wage adjustments and potential labor strikes, reflect broader trends in consumer behavior and corporate stability.

---

Conclusion The episode provides a comprehensive overview of the current challenges facing major companies like Apple and the opportunities presented in the burgeoning weight loss drug market. The discussions highlight the intricate balance of market sentiment, geopolitical factors, and economic conditions that influence investor decisions.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:01Live from the Nasdaq market site in the heart of New York City's Times Square. This is fast companies like Nike, Tesla, Qualcomm be right now. A deep dive coming up. Plus, a$100 billion opportunity. That's how big, J.P. Morgan says, the market for weight loss drugs could be. Just how much could that mean for the biggest players in the space? We'll debate that. And later, are you ready for some football and some sports betting? NBC's magic wall maestro, Steve Kornacki, will be along to take us inside the numbers. I'm Melissa Lee coming to you live from our brand new set, Studio B at the NASDAQ.

0:46On the desk tonight, Tim Seymour, Karen Feinerman, Bono and Eisen and Steve Grasso. We start off with the second straight rotten day for Apple. Shares down another 3 percent today. They are down more than 6 percent over the past two sessions. The biggest stock in the world has also been the Dow's biggest loser two days in a row. The slide starting after report China will expand its iPhone ban to state-owned companies. Semi is tied to Apple also feeling the heat. Qualcomm, for instance, down 7 percent. Taiwan Semi down more than 2 percent. So is this just giving us a taste of how big the impact of a China crackdown could be and what other companies could face the wrath of Beijing next.

1:22We have been saying this again and again. It is just up to China to decide how big the restrictions will be. And I think we have to be careful not to overstate what has happened here. Too late. You're right. This is what happens in financial media. But the fact that you can't use your iPhone at work doesn't mean you can't go out and buy an iPhone and we're banning this company. And Tim Cook, of all the major CEOs, and obviously it's the biggest company in the world, has done a fantastic tightrope act here in trying to balance. There are social issues. There are dynamics around the economics. There's Foxconn.

1:55There's everything. I think this is important. I think it's important because, in fact, it does look like on some level China is responding and fighting back. I think what is more important to this news cycle is that it's coincident with the release of a very important phone in China, the Huawei, the Mate 60, which has chip design, which has seemingly been able to either kind of reconstitute a 5G phone without having 5G chips because Huawei is under major, major bans and restrictions from the U.S. I think it comes at a time when Apple's had three straight quarters of declining sales. And I think what it does is it just projects what's the multiple you want to put on this company.

2:32It doesn't change Apple's business that dramatically, I think. I think the concept of what we're talking about, we're going to continue to talk about and we should talk about it. I just want to make sure we're not overstating this news. But the context is also that China's macro looks awful right now. And there are already headwinds there for the Chinese consumer. And so you add to this, you know, hey, you know, you cannot use an iPhone at work. Maybe that person chooses a Huawei phone and not an Apple phone. And incrementally, that could still hit revenue there. I think that's a bigger issue, actually.

3:03Can the Chinese consumer afford to keep buying iPhones at the same pace, right? That, to me, is a bigger issue. And to me, also, it's about rates having moved up and multiples needing to move down. And they were getting such a big multiple. Steve and I were talking about this in the green room. There's a hardware business, much bigger, and a software business, and a high multiple of 30-ish. If you back out the hardware, the software business is trading at way higher than 30. And so we've seen multiples for those kinds of businesses come down. So this is kind of an excuse for the sell-off. Yeah.

3:33But I don't think in and of itself, this news should be at eight or nine percent move in Apple. I just think that it was too high. You know what I think? Investors are in a situation where they're shooting first and asking questions later. And I'll be honest, I never thought that would be the case with Apple. That's the biggest shocker there for me, that the selling is coming before any material development in this particular news cycle. Now, it's lost about 200 billion dollars of market cap. Now, you really want to ask yourself, is the move really worth that? I would say and prognosticate no.

4:06However, I think that speaks to the fact that we just don't know that there is some volatility around the situation. And given the whimsical nature of what the Chinese government may do in retaliation, will they keep it here? Will they expand it to state-owned enterprises? Will the bans be, you know, will there be somewhat of a shadow ban where it's implied that you really shouldn't really, you shouldn't affiliate yourself by purchasing the phone? So we truly don't know. So I don't think it's a complete surprise, given the rate environment that you mentioned, that there was some sell off. I mean, global companies view themselves as global companies.

4:37But in China, a lot of times companies are viewed as, you know, belonging to a nation. It is a U.S. company. And that's the way Apple is. Well, Tim stated it on the opening. Tim Cook and Elon Musk have done a masterful job. Those are the two CEOs that have done a masterful job at being agnostic. So if there's anyone that's not considered U.S. and just independent, it's those two. That's number one. Number two, Bono and said that he's shooting first. I don't think they shot first because if you look at it, it's only down 8 percent. Right. Guy sat here last night and said, shouldn't it be down more if you're shooting first and not asking questions?

5:16And then getting back to the amount of phones that are really in question. Dan Ives is talking about that he sees it as being 500 ,000 phones. The market is probably pricing in 5 million phones at this point. So they are shooting first. The problem is they're running out of bullets. So you saw this stock today. It bounced. Does it continue to bounce? I think so. I bought it yesterday. I bought it again today. I don't think that anyone should rush out and buy 100 % of whatever they think their position is going to be. But when you look at the services arm, that's growing. That's the growth. So Karen talks about hardware.

5:51They're separating themselves from the hardware dynamic of being that company. Yes, they get an exorbitant multiple, but that's where the growth is going to be coming from. The install base is incredible and only growing. In terms of proof, Bank of America had an interesting note saying that, you know, you should take a look at App Store revenue in the coming quarter, because that's where you will see it. If App Store revenue slows down, because in China it's 26 percent of total revenue. That's impressive. And it's the higher margin revenue. It's a higher margin revenue. That's where you'll see it.

6:23So we'll get that data in terms of how effective that ban is in terms of being enforced and so on. And I bring us back to yesterday's news also around the EU. It seems to me like the EU is really looking at the app store and they're calling them a gatekeeper. And but I think there's multiple dynamics there. We're talking about the multiple. We're talking about the global macro. I think we have to talk about also just within within the market space. And we talk about equal weighted ETFs versus market cap weighted. And look, what we know in the data that we're getting is that the data flow is going to equal weighted ETFs.

6:56You look at today, though, let's be clear. Apple was a significant underperformer to Google, to Amazon, to anyone else in the mega cap tech space. It's not by accident. And I think it's a combination also, though. Let's highlight. I mean, September 12th is a big day for the company. And yet it's, you know, that's the whole point. If September 12th and the release of the 15 is not that big of an event, I'm not saying it has to be that big of an event. And I'm sure you'll point out, Steve, that they haven't been big events for a long time. Right. But they normally run up into that event. So maybe now that event won't be won't be the sell on the news day that it's normally been because it's sold off prior to that event.

7:37So that's I just think it's not a coincidence, though, that you're running into this kind of pressure. Also coincident with the big release date. Right. And the semiconductors. I mean, we mentioned Qualcomm and Taiwan Semi, but if you take a look specifically at the Apple supplier, Skyworks was down 7 percent. Cirrus is down something like 4 plus percent. Yeah, I mean, Apple was one of the biggest beneficiaries with this Huawei ban. So I don't think it should come as a complete surprise that they're going to give up some of that value. They added massive market value, mainly at Huawei's expense.

8:06So I would expect there to be some collapsing of that divergence that we saw three years ago. I think to put it in context, as we all have been really trying to do here, we still don't know all of the data yet. And it's going to start trickling out. Eight percent perhaps isn't a complete kill shot, but that's a material move for a name. It's a first name that people rush into when they go to deploy Apple. And the big thing is the triple Qs. You said it last night. As Apple goes, so does the market. Is that the question? And you have Apple, Microsoft and Amazon account for 25 percent of the Qs.

8:39So if this starts to expand, that's not just Apple and it's all of those top names. Then how do you mount a rally? Because if those names don't perform, the market doesn't perform. That's the question. You know, you hold Nike. We've been saying this for a long time, Karen. Just, you know, the exposure that U.S. companies have to China in terms of, you know, the thesis that that's going to be the growth market. And it used to be. And it used to be. Right. And now maybe that's a discount to the business. I'll say this. In terms of incremental growth of one's business, I mean, the aggregate base in China may not be growing as fast, but it's still a massive base to go out and attack.

9:16And a lot of these brands are still going there. But this also comes – there was terrible export data out of China. So, I mean, it's what we say. Part of this is the Chinese economy. Part of these are the geopolitics. I don't think the geopolitics get better. I think they get worse. It's also interesting that on a day when semiconductors got slammed, Intel, the American flag-waving chip play, was up big. And I think it's more than a coincidence. I mean, I think there are home team favorites. There are national champion companies. And Intel hasn't really covered itself in glory in this country relative to its global peers.

9:49But I think that has something to do with why it was higher. Our next guest says global companies are going to have to fight to be in China. CNBC contributor Dewardrick McNeil joins us now. He's a managing director, senior policy analyst at Longview Global. DeWardrick, great to get your take on this. Do you think that it gets worse? Do you think that when you take a look at other companies that do business in China, where there are alternatives, in theory, that China will favor the home team or another team that's not a U.S. team? Well, you raise an interesting point here, Melissa. So the real question is, have we entered an escalatory, retaliatory, tit-for-tat cycle like we saw during the trade war?

10:31And if we have, and it's possible that we have, then there are some sectors, some companies that I think will have some challenges. I think in aviation, Boeing, I think China has an alternative in their mind. They're happy to play Airbus off of Boeing. They also have a domestic brand, the Comac C919 or C929 as well. So they think they have an alternative there. Automobiles. Look, Tesla, we've been talking about this for quite some time. GM possibly are at risk with BYD. You know, just this past week, we saw BYD in Europe at the Munich Auto Show. And their message was, we're beating you in our home market.

11:13And we're coming to Europe to beat you in your market. So, you know, I think there are a lot of concerns here about whether or not we are, in fact, in this retaliatory cycle. And if we are, Melissa, even though companies may see themselves as multinational brands or global companies, frequently governments and citizens, particularly nationalist citizens with the rising populist movements around the world, don't see companies as multinational. They see a flag attached to them. And if you go into China, you have to understand there are a lot of competitors there. You're going to have to get into a competition mindset.

11:52And the Chinese have their own widgets. And they're looking to sell them, not just in China, but in third markets as well. Duarte, it's Karen. Thanks for being on. Is this some of this on the heels of Secretary Raimondo's visit? What kind of happened? Because it seemed like the rhetoric escalated after that. Look, I think the Chinese have been sort of hot under the collar for quite some time about the way their businesses have been treated. And this was a great way with the Huawei announcement moving to seven nanometers, something that the Commerce Department actually has been very involved in in terms of the chip ban.

12:30All of this is coincidental, but too coincidental for those of us who watch China. I think the timing here says a lot about what China is looking to do. And it's really to send a signal that we are not going to be stopped. You can slow us down, but that we will continue to do what it takes to have indigenous development, to be self-reliant to the degree that we can. And this is the challenge, Karen. I'm not sure if they're going to win this over the long term, but I think they certainly feel comfortable that they send a strong signal right after Secretary Raimondo's trip. And, Wardrick, it's Tim.

13:06You've also said in your notes, I thought this was fascinating. It's kind of what you're saying here. China rarely takes actions that will harm China with no alternative. Is the point now that Huawei is ready? Is the point now that we really feel like we've actually and, you know, this this phone sold out in hours and it's priced below Apple at a time when the consumer is under pressure? And it's not a low cost phone. I mean, it's nine hundred sixty five dollars. But is the point that Huawei is ready to challenge? And as you say, China would be OK if they had to actually push on in a world where there was really more opposition to Apple.

13:37Yeah, I think that's the message here, Tim. I'm not sure that they are ready. I think you made a point before I came on about sort of right sizing this news. This Mate 60 is an impressive phone. I think it surprised Washington for sure. But it's seven nanometers. Apple in a couple of days here will debut their 15 Pro. That's a three nanometer chip. So there's still a lot of room here between seven nanometers and three nanometers. But the Chinese are very comfortable that they don't have to be the best. They just have to be good enough to dominate their market. And quite frankly, the Mate 60 Pro may be at seven nanometers just good enough.

14:17And so that that's the question that I think we have. But it certainly got the attention of many here in Washington. So we may see when Congress returns a discussion about a broader yard and a taller fence, as Jake Sullivan likes to say, about small yards and high fences here. So last quick question to Warder because we're just about out of time. But, I mean, it sounds like you think this gets worse. I'm fearful, Melissa, that we are entering into a tit-for-tat retaliatory cycle. like we saw during the trade war. And to Tim's point, and I've made this point in my notes, China's going to look for places where they can do this, where they have an alternative.

14:59Think about what they did with soybeans. They had a reliable alternative with Brazil and Russia. And so they were prepared to really level on the tariffs for soybeans. You'll see some of the same action if we are, in fact, back in one of these escalatory, retaliatory ladders. I hope not, but I fear that we are. DeWordrick, thanks. Good to see you. DeWordrick McNeil, Longview Global. We have some pretty good options, too, right? So there's India, there's South Korea, there's Vietnam, there's other options. So China is not the only one with options. And Karen just said, what happened after Secretary Raimondo was there?

15:33She got hacked, right? So she got hacked and she was not happy with that. And she told the Chinese officials that she was hacked and was not happy about that. So that's what's been ratcheting a lot of this, I would guess. And yet you still bought Apple twice. Yeah, because I think that China's all bark, no bite at this point. I think we have them versus they have us, to be honest with you. All bark, no bite. I know I'm not willing to go there. I definitely think they have a bite. I think I think whether or not their bite is as vicious as they think they're willing to bite. That's the scary thing.

16:03As Dwarjik said, the distance between a seven nanometer and a three nanometer. Four nanometers. Nice. In their head, she did that like that. That's a good math. Wow. He went to Harvard. But it is a big difference. Yes, in terms of the implications of the technology. And so the fact that they're flexing their muscle there seems like an insignificant tit for tat, or at least an irresponsible one. I think the barriers to entry in terms of being able to produce soybeans are light years different than being able to produce that technology. All right. Meantime, Goldman Sachs CEO David Solomon just wrapping up an exclusive interview with our own David Faber, the bank's chief, addressing a wide range of topics from the company's performance to the IPO market to his own portrayal in the press.

16:42David Faber joins us from Goldman's Cornucopia, Cornucopia, Communicopia Conference. It was a Cornucopia. That one's that's one that one is in November. It was a Cornucopia, too, Melissa. But good job on the math there between seven and three. You got that going. Yeah. And listen, as you might expect, of course, we spent a good amount of time on that very unusual spate of stories from major news organizations that really dealt with the subject of Mr. Solomon's personality and whether, in fact, it was getting in the way to a certain extent of his management of the firm. But, you know, for our purposes, of course, his comments about the capital markets and M &A certainly perhaps more centered for what what, again, we care about.

17:26And we've got a couple of big IPOs coming next week. You guys will be talking about that a lot. At the NASDAQ is going to be Arm pricing on the 13th to trade on the 14th of September. And I did ask Solomon, you know, overall, is he feeling a bit better about the IPO calendar and the capital markets as a whole? I definitely do feel better about the capital markets. And if you ask me to kind of look ahead, you know, over the course of the next few months, especially if Arm and some of these other IPOs, you know, go well, I think you're going to see a meaningful increase in activity. Now, David, it's often an anemic amount of activity.

18:03I mean, nothing happened last year. Nothing. No. I mean, it's really investment banking activity. If you go back to the second quarter, investment banking activity in the second quarter was a 10-year low. And so it's not hard to improve off of that. But I think we could very quickly get back to what I'd call a more normalized level of activity in the capital markets. And that's obviously very, very good for Goldman Sachs. Of course, Instacart will soon follow potentially, guys. So, you know, a lot to focus on when it came to M &A. Solomon also kind of a more positive forecast, at least, talking about dialogue starting to pick up.

18:39That's something I've been hearing as well and sort of just talking to many of the practitioners, whether they be lawyers or bankers, in terms of at least conversations, which, of course, need to take place before you can actually get announcement of deals. He sort of indicated that'll be fourth quarter and into 2024. But those are still the key businesses for Goldman Sachs, obviously trading in the capital markets and advising on M &A. a Melissa far more than the roughly 5 % that consumer banking represents, even though, of course, that also, in addition to Mr. Solomon's personality, has gotten a lot of attention of late.

19:12Is he DJing less? I'm only half joking because that was one of the many gripes, personality defects, I think you said to David Solomon, highlighted in these numerous articles about him and his tenure, the fact that he's a DJ on the side. And so I'm wondering how he sort of tried to reclaim his image. Yeah, you know, I think it's a process. I think for my purposes today, we asked those questions that I think felt necessary to ask, given, again, that really unusual spate of publicity specific to so many different anonymous quotes, basically saying he's a very difficult guy in nice terms. I did ask him if he's going to DJ again.

19:57He didn't answer the question. I kind of took it as a no. And I think, Melissa, it's been as much as a year since his last appearance, as far as I'm aware. So that is something that he has clearly cut back on as well. All right. David, thank you. David Faber joining us from Communicopia out west. We bring this up because, you know, it's always fascinating to talk about personalities when it comes to CEOs. But for a time, there were questions about whether or not he would continue to be CEO or whether his days were numbered. Right. Are you saying that as if those questions are no longer there? I don't know.

20:32I don't know. I think that at one point the drumbeat was loud and steady. And it's not as much anymore. Well, they did. I think he was trying to talk a little bit about, OK, we're past that consumer business. Right. Right. Right. So that was obviously a big waste of time. Money, resources didn't work out. So good for them for exiting it. It's amazing to me that Goldman Sachs, which really think of as, you know, the best of the best in a lot of ways, trades at 1.1 something times tangible book value. That's kind of amazing to me. And yet I haven't felt compelled to own it. I think, you know, if they're talking about M &A, investment banking, those sort of revenue streams don't trade at a great multiple.

21:12So even if activity improves, I don't think that's as solid footing as, for me, J.P. Morgan is the place to go. All right. Coming up, a UAW strike could be just days away, and the union just responding to the latest proposal from one big automaker. The details and how a work stoppage could impact the entire industry next. And up, up and away, we are getting in on the greenback with the dollar on pace for an eight-week winning streak. So how are the options pits cashing in? We'll find out when Fast Money returns.

21:48Welcome back to Fast Money. The clock is ticking on a potential strike in the auto space. The president of the United Auto Workers, calling GM's latest attempt to sidestep a stalemate, quote, insulting. Our Phil LeBeau has more on these negotiations. Seems like we're at a standstill, Phil. We are. And yet at the same time, there's progress that is being made. I mean, it's not like there's no negotiations and they work on a bunch of stuff before they get to the really meaty stuff. And that's always at the very end. Here's what's happening today. As we speak, representatives from the UAW are meeting with Ford again.

22:19Ford's giving them another counter offer, whether or not Ford releases that. I don't think they're planning on doing that, but who knows? And then there is General Motors. If you take a look at shares of General Motors, today the company said, okay, you want a counter offer from us? Here's our counter offer. 16 % over four years, 10 % initially, and then two lump sum payments over the course of four years of 3%. That's how GM gets to 16%. Also a$5 ,500 signing bonus. There's usually a signing bonus when these contracts are ratified. So a few hours after that was released, what did the UAW say?

22:53Sean Fain did not mince words again, calling it not only insulting, but then going on to say, GM either doesn't care or isn't listening when we say we need economic justice at GM by 11.59 p.m. on September 14th. The clock is ticking. Stop wasting our members' time. Tick-tock. Very dramatic. Similar to what we've heard from him, whether it's with GM or Ford, throwing the proposal into the garbage can on Facebook Live. This wall, do we have the wall? The wall showing it's really all about whether or not the automakers can afford to pay or how much more can they afford to pay. And you see where they are relative to the foreign automakers in the U.S.

23:34And then there's the estimate for Tesla considerably lower. By the way, with regard to Ford and Stellantis, there's the counteroffer talks that are going on this afternoon between the UAW and Ford. They've already had a couple of offers from Ford. Stellantis will be making another counteroffer tomorrow to the UAW. Bottom line is, I don't think we see anything really until middle to end of next week. And again, most people I've talked with in the auto industry do not believe that this is going to be resolved by next Thursday at 11.59 p.m. Wow. So 97 percent of members have voted in favor of a strike.

Read the full transcript

24:09Well, they voted to say to the union leadership, you think it's time to go and call a strike, then call a strike. Yes. That's normal. That is normal. That happens every four years. All they're saying to the leadership is you ultimately make the decision and then we'll go from there. What is GM's leverage at this point? GM's leverage. GM's leverage to the rank and file is, do you really want to go through with this? We're going to give you a healthy raise and we're not going to give you 40 percent. Nobody's going to give them 40 percent. But 16 percent is not going to cut it according to the UAW.

24:43And now the question becomes, how much more can they afford to pay? I think a great stat came from Adam Jonas, I want to say about a week, week and a half ago. Take a guess. What percentage of Ford's global revenue, annual global revenue, is eaten up by UAW costs? Four percent. Yeah, you are right. But how much if they if they give them, let's say they give them 25 percent, how much more is that going to hurt them? Maybe a percentage and a half, according to Adam Jonas. So it's not the end of the world. But it is substantial. If you're forward, you're looking at it saying, wait a second, that's really going to cut into our margins.

25:17And I think Adam Jonas said maybe a 20 percent hit on the on the even margins is what his estimate is if they did that. So, you know, they'll come to an agreement. We all know that, but I do think that we're trending towards a strike. All signs, everybody I've talked with said we are headed towards a strike. But a strike's ultimately going to be destructive for both sides. And you've seen this before in terms of the negotiation tactics and how these stocks trade. And I realize we're supposed to be the traders on this. But there's no question to me that we've been pricing in this news for a long time.

25:48I mean, Karen and I sit and bang our heads on the desk every night about GM, and it's multiple. And ultimately, how effective they've been on their execution and really where they've been on free cash flow. So I feel like this is this is a great time because we've exhausted all of these arguments on both sides. And at some point there is going to be some clarity here. It may not be good, but it's going to be clarity. And these stocks are getting destroyed on the lack of it. So, Phil, how much do you think the I understand strike seems inevitable at this point. But at what point does the workers start to get fractured in there?

26:20Does the solidarity get fractured? It's not like the writer's strike where a lot of them aren't working anyway. Right. So this is a different dynamic. It is a different dynamic, but it's a different time from this perspective. I think that whether you're a UAW member or any other labor union, you've got a little bit more cash cushion than you had, let's say, eight years ago. You just feel a little bit better in terms of being able to withstand a strike. It doesn't mean you like it. It doesn't mean you're like, yeah, sure, I'll walk off the line for five, six, seven weeks. You're going to get$500 a week if you're striking.

26:55Now, look, if you're not at a plant that goes on strike, you're going to get laid off. You'll have to file for unemployment. That's how it usually works. And, you know, you're not happy about it, but you're ultimately you're buying into the idea. I'm going to get X percent raise at the end of the day. And I got to go through this. Phil, thank you. Phil LeBeau. There's a lot more fast money to come. Here's what's coming up next. Another day, another dollar gain. More like another week. The almighty greenback about to notch an eighth straight week of games. And the options pits are throwing their two cents in on the currency's next move.

27:32Plus, weight loss drugs working wonders on the waistline. But the potential market is doing anything but slimming down. Just how big the industry could grow to be. You're watching Fast Money, live from the NASDAQ market site in Times Square. We're back right after this.

27:56Welcome back to Fast Money. The U.S. dollar is about to do something it hasn't done in more than eight years. The greenback is on pace to notch its eighth straight week of gains for the first time since February 2015. But options traders have their eyes on another major currency that could rocket higher. Mike Coe has the action. Mike. Taking a look at FXY, that is the ETF that tracks the Japanese yen. Obviously, that's been very weak all year. It traded more than eight times its average daily call volume today. The busiest contract were the January 2025 66 strike calls. We saw buyers paying about $3.80 a contract for those nearly 1 ,200 traded hands.

28:33Also very busy, the 68 strike calls. Buyers of these are expecting FXY to go above 70 in the next year or so. Thanks for that, Mike Coe. For more Options Action, tune into the full show. That's tomorrow, 5.30 p.m. Eastern time. Coming up, just how big could the market for weight loss drugs be? One analysts is looking for a huge surge. What it means for competition in the space, even as a new use case is being investigated, the names that could see outsized gains next. Plus, Walmart giving a new spin to the term rollback, the move by the big box retailer that could give the real read on the strength of the labor market.

29:07We'll discuss that when Fast Money returns. Missed a moment of Fast? Catch us anytime on the go. Follow the Fast Money podcast. We're back right after this.

29:26It's welcome back to Fast Money Stocks. Mixed to end the day, the Dow up 57 points, the S &P down three tenths of a percent, and the Nasdaq down about nine tenths of a percent. Now in a four-day losing streak. Some after-hours movers here. Shares of DocuSign higher after a top and bottom line beat, and RH dropping after issuing weak Q3 revenue in operating margin outlook. Meantime, a huge call from J.P. Morgan sending shares of Novo Nordisk And Eli Lilly hired today analyst Chris Schott, saying the U.S. diabetes and obesity drug market could eventually hit$100 billion in sales a year. It could crack$50 billion by the end of the decade.

30:03Eli Lilly, one of the biggest players in the space, hit another all-time high today. For more, let's bring in Mizuho healthcare sector strategist Jared Holtz. Jared, great to have you with us. Great to see you. Thank you. You know, it seems like these drugs, GLP-1s, they could be the cure-all for not just, you know, obesity, but for diabetes potentially entirely in terms of eliminating the use or the need for insulin in terms of addictions of all sorts, in terms of Alzheimer's, in terms of sleep apnea. So why should we be skeptical when a note comes out and says$100 billion eventually? It's a cure-all drug, it seems.

30:41I mean, maybe we shouldn't be at this point. I think the reason to be skeptical probably comes down to a couple of things. It comes down to, you know, how big of a target these drugs wind up being for payers, the managed care companies, and how they kind of navigate the next several years from a demand standpoint and from a pricing standpoint and an access standpoint. That would probably be, you know, maybe the biggest deterrent. And then the second is just pricing longer term. But if these drugs are really cure all is like, you know, we're kind of finding them out to be, you know, then maybe the amount of skepticism with respect to the market size we have to kind of think about a little bit.

31:27Are we sort of in a Goldilocks place right now where the belief and the hopes for all these drugs are still in the stocks? And we're not yet at a point where it is proven that it will reduce cardiac events. It is proven that it will reduce the symptoms of Alzheimer's. Because once these things are approved medically, then they became targets. eventually, I would think of government negotiations and other sort of price controls, scrutiny by the U.S. government in terms of the ability to price these drugs. Totally. I agree with all of that. I think that as time goes on and we kind of see what the net effect is for patients that are on these drugs longer term, you know, we're going to kind of find out what the real opportunity is.

32:14And yes, I think we're We're talking about some really blue sky scenarios for Novo and Lilly here, and they're probably not unfounded. The stocks have been incredible performers, outperformed every other pharma company, pharma stock in the peer group. This is the core reason why. And we'll kind of have to see over the next few years how this all plays out. But, you know, to have a small study in the New England Journal from the University of Buffalo that had less than a dozen patients have this profound effect on the stocks and then also have an impact on the broader diabetes space on the medical device side is very, I think, significant because these studies are going to continue to happen and they're likely going to be larger in scale as we move forward.

33:00Jared, it's Karen. Thanks for being on. So it sounds like you're a little bit skeptical. I mean, this number, that's a big number,$100 billion. And yet their price target was$600, which is really not very far at all. One day, one, two days trading away from where we are. You sound a little more skeptical. Where do you think, how far ahead of these big numbers do you think the stock might be now? Well, Karen, I'm not so skeptical that the revenue numbers can get to these levels, 50 billion, 100 billion over time. It's theoretically possible. If the price point is where it's at now. You know, it doesn't take that many patients to get to those type of levels.

33:38So I'm not super skeptical on that. I just feel like the very, very bullish outlook and the estimates that are out there are probably not all that helpful for the stocks over the course of time as the bar becomes so high. And if for any reason they should stumble along the way, that's where I think you run into a problem. I mean, it just doesn't have the same appeal where by the analyst community kind of like allowed for beats and raises with$100 billion market size. I just don't know how much more we can get over the next couple of years in terms of modeling. As Lilly and Novo, as the story there gets better and better, it seems like the story gets worse and worse for a Dexcom and a ResMed.

34:25And we've already seen the impact on ResMed very clearly. They, for instance, are going to be speaking at the Bank of America healthcare conference next week. What is the narrative that these CEOs can give investors at this point to say, you know what, our business is not going to be eaten away by the impact of these semaglutides? I don't know what the narrative that they're going to kind of portray over the next couple of weeks is going to be. You know, a couple of these companies are at broker-sponsored conferences in the healthcare arena this week, and they've tried to dispel some of the worry or apprehension as far as what the GOP-1 category is going to do to their businesses, particularly on the diabetes side, and it really hasn't worked overly well.

35:12I just feel like, you know, I really want to take a step back and reassess some of these stocks in the medical device space. I just don't know if they're going to work because this overhang is going to persist for a number of quarters, years to the point where I really don't know what management teams can say to get investors to think there's nothing here. Jared, thanks. Always good to see you, Jared Holes. Steve, where are you on this? Yeah. So, I mean, Novo and Lilly are by a large margin, as Jared said, outperformed the entire group. But I think that the problem, though, is that not everyone who is classified as obese is going to run out and take a pill.

35:52So ResMed's getting hit hard. And I'm not saying go out and buy the stock now, but they're assuming that everyone with a weight issue is going to take a pill. And I don't think that's the case. Not everybody with a weight issue, but it's some people with weight issues, some people with cardiac issues, some people with Alzheimer's, some people with addictions. And you add that up, it's a huge market. They're already taking those pills, though. I hear you on the holy grail, but they're already taking pills. somewhat of the same conclusion, a different path. How do you project out the revenues around these drugs when you just saw what's happened with the Medicare negotiating?

36:26So, for instance, fine, even if all of those use cases are applicable, how long do these people have to be taking these drugs? And are the dosages staying? Are they becoming more intermittent? So I just don't really see how there's much upside left that has not already been priced in. Coming up, Are you ready for some football? Get ready to place your bets because kickoff is in a few hours. We're talking touchdowns and fumbles in the sports betting space ahead. But first, Walmart is rolling back. Pay. What that could say about the state of the labor market, those trades and more when Fast Money returns.

37:06Welcome back to Fast Money. Walmart's latest rollback is hitting employees' paychecks. It's a big box chain cutting its hourly wage starting pay for some new hires. The retailer is saying the move is meant to normalize wages across positions. But what does this say about the state of the labor market that finally they're able to say, you know, we're not going to pay as much? Maybe that's a good thing for these retailers and for businesses. Yes, and I think it's a good thing for the Fed, right? I mean, this is what they wanted. If they could get either higher unemployment, which isn't ideal, but it's an acceptable sort of collateral damage, or lower wages, that's helpful.

37:41However, for that consumer, who is that Walmart worker, right? He's getting less. He's getting less. We've already seen them be a little bit sort of, you know, pinched between gas prices. It's net-net, I think it's probably good for the market. Coming up, we're ready. We are ready for some football. And our favorite political watcher turned pigskin pundit is here to handicap which teams are in the best shape. To win it all this season, we'll kick things off right after this quick break.

38:17Welcome back to Fast Money. Place your bets because football is back. The NFL season is about to kick off in just a couple of hours with the Detroit Lions facing off against the Kansas City Chiefs. NBC's Steve Kornacki joins us with a look at the betting odds and some of the preseason favorites. Hey, Steve. Hey, how you doing? Yeah, we are about two and a half hours away from kickoff 2023. What we got here, these are the final preseason odds heading into the season. We've broken them down by conference. These are the top seven in each conference. So there are some other teams you don't see here, but these are sort of the top choices in each conference to win the Super Bowl.

38:50And you see the overall favorite across both conferences to win the Super Bowl this year. It's the Kansas City Chiefs. They are favored to repeat. They are 6-1 as we enter the season. The second choice right behind them, it's the team the Chiefs just beat in the Super Bowl last year. The Philadelphia Eagles, they start out at 13-2, basically 6.5-1. So Eagles, Chiefs, the oddsmakers are thinking rematch, of course, in the entire Super Bowl history. We've only ever had one rematch in a Super Bowl of the previous year's Super Bowl. That was Dallas-Buffalo. That was about 30 years ago. Some other notes here on this screen here.

39:28How about the Jets? You don't usually see them with odds this low, with expectations this high. That has everything to do with Aaron Rodgers going from Green Bay to New York. Huge expectations there. The Cowboys sitting at 14-1. Are they snakebitten in the postseason? They haven't been to the NFC title game since the 1995 season. But again, they look like, at least on paper, a contender this year. So you see the Chiefs as the overall favorite to win the Super Bowl. How does the overall favorite typically do? Well, typically, I don't want to say it's a jinx, but they usually don't win the Super Bowl only twice in the last 15 seasons has the preseason favorite actually gone on to win the Super Bowl.

40:08A number of them have made it and lost. The last three Super Bowl winners, though, and this includes the Chiefs last year, were double-digit odds in the preseason. The Chiefs were 10-1 a year ago. The Bucs were 10-1. The Rams were 12-1. So recent history says it's not going to be one of those long, long shots, but it's not necessarily going to be the favorite either. If you take a look at this matchup tonight, as we say, the Chiefs, they are seeking to repeat. They're at home here. Question mark about whether Travis Kelsey is going to be playing, and it's the Lions. Big expectations in Detroit for the first time in a long time.

40:43They've only won one playoff game in 65 seasons. Hey, Steve, it's Tim. So, first of all, if the New York Jets were a stock, we'd probably say they were trading at 80 to 90 times multiple, which means crazy, crazy expensive. I'll leave that for somebody else. is the proliferation of online sports betting, has that changed the way these lines move around before the game? It seems like if we were stock traders, again, which we are, we'd say the market's as deep as it's ever been in terms of the amount of people being involved in online sports betting. No, and we actually use the Jets as an example because we just showed you, I go back to that screen, the Jets are 16-1 here to win the Super Bowl.

41:20When they opened betting a few months ago, the Jets were 40-1. Wow. So the public reacted to that Rodgers move. And there's really you could see the hype building there right now. They've gone from 40 to one all the way to 16 to one. Awesome. Steve, always a pleasure. Thanks so much. You got it. NBC's Steve Kornacki. That's awesome. So we'll trade it as traders. We're not trading the teams. We're not trading the odds. OK, we're trading. We're trading tonight's game. No. Oh. Want to trade tonight's game? Now we're going to trade sports betting stocks. Yeah, this, I mean, it seems like there's only one sports betting stock.

42:03DraftKings seems like they ran away with it. So if you look, everything else is so warped. It's the only direct play. But I just put$10 ,000 on Minnesota to win everything. You see them 35-1. Nice. Who's your pick? I think DraftKings is the way you play it. I mean, my personal pick for the games are 49ers, but I'm getting ahead of myself there. All into the hype chain. But I think DraftKings is the way you do it. I think Penn was there neck and neck for a while, but I think there's been some changes in that landscape. Karen's actually a football. Yes, she is. I'm knowledgeable about football. Is that true about the Lions?

42:37One playoff? Lions, Tigers, and Bears, Karen. One playoff game? In 65 seasons? Wow. What do you think about Kelsey being out, though? You were talking about that. I know. Well, that's – we were talking about how important is the tight end. Well, when Mahomes is the quarterback. Any team with Patrick Mahomes. How important is the tight end for you, Karen? When they shuffle the wide receiver. By the way, you can catch tonight's game between the Lions and the Chiefs on the big network. NBC coverage kicks off in just over an hour from now, 7 p.m. Eastern time. Up next, Final Trades.

43:13fun day for our fast money family ringing the opening bell here at the nasdaq to celebrate the show's 16 plus years of broadcast wow and the launch of our newly designed set here in studio b the reimagined nasdaq market site cnbc president casey sullivan joined me the traders of course our entire production team folks behind the scenes who makes it all happen uh that happened this morning at this event here. It was fun. It was exciting. It was exciting. And I'll tell you what, our friends at the NASDAQ, too, I mean, they built a beautiful set. Our friends at CNBC have helped them, and it's a home like we've never seen.

43:47It's exciting. Time for the final trail. Let's go around the horn, Tim. Intel. Again, if you think about the iPhone ban or whatever that means, more broadly, I think it actually shines a very bright light on U.S. players, and we know what the story needs to be at Intel. I think it's their time. Karen? Yeah, I think it's actually time to sell some upside calls in Holy Grail, which is Eli Lilly. It's running so far so fast. Not that it isn't great, but. Bono in. It's under-owned and the trend is strong. XLE. Rosso. Ethereum Trust. I've used this one as my final trade before. In January, it was four and change.

44:20In June, it was seven and change. It was nine and a half in August. This thing is going straight up now. It's almost 12. Mad Money starts right now. All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBC Universal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.

44:51Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. To view the full Fast Money disclaimer, please visit cnbc.com forward slash fastmoneydisclaimer.

From the publisher

Apple dropped for a second day in a row, and this time major suppliers came along with it. Is this just the start of what a China crackdown might do? Or are companies from Nike to Starbucks also in the crosshairs? Plus one analyst out with a big forecast for how large the weight loss drug market could get. What it all means for the biggest players in the space.

 

Fast Money Disclaimer


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
Could China’s Crackdown Go Beyond Apple? And Just How Big Can the Weight Loss Market Get? 9/7/23CNBC's "Fast Money" · 45 min
Listen in VO